Autologous bone marrow transplantation for acute myeloid leukemia.
Despite progress over the past three decades, most patients with acute myeloid leukemia (AML) treated with conventional chemotherapy alone relapse and die of recurrent leukemia. Treatments used to improve outcome include allogeneic (alloBMT) and autologous bone marrow transplantation (ABMT). Indications for transplantation and the relative merits of alloBMT and ABMT remain unclear. In this review, we evaluate evidence supporting a role of ABMT in AML and compare the results with outcomes after alloBMT. In addition, we discuss areas of controversy including the optimal timing for ABMT, the role of bone marrow purging, the place of peripheral blood stem cell collection, the high dose regimen, and post-transplant immunotherapy to reduce relapse.
Imrie
K
K
University of Toronto Autologous Blood and Marrow Transplant Program, Ontario, Canada.
Dicke
K A
KA
Keating
A
A
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D006801:Humans; D007951:Leukemia, Myeloid / Q000628:therapy*; D016032:Randomized Controlled Trials as Topic; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous